B2PRIME
10.6.2024 13:19:26 CEST | Business Wire | Press release
B2Prime, a leading global multi-asset and multi-market Prime of Prime liquidity provider, and Spotware, a premier and innovative trading platform provider, have announced a strategic partnership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610848632/en/
B2Prime, a Prime of Prime multi-asset liquidity provider, and cTrader, Spotware's flagship trading platform, have established a strategic partnership to expand trading opportunities. (Graphic: Business Wire)
The cTrader platform by Spotware is renowned for its advanced features that cater to professional traders:
Clear and stunning UI → Visually appealing and comprehensive user interface with a possibility for deep customisation.
Multi-asset trading without latency → A diverse range of supported asset classes alongside lightning-fast order entry and execution.
Depth of market (DOM) → Level II pricing empowers traders to evaluate market sentiment and anticipate potential price movements with higher accuracy.
Top availability → cTrader offers cross-platform accessibility with its Desktop, Mac, Web and Mobile (iOS and Android) apps.
Advanced risk management → cTrader users are equipped with sophisticated protection tools to trade with confidence.
Algo trading solutions → Out-of-the-box ecosystem for algo trading, with cBots, indicators and plugins.
Social trading platform → cTrader Copy is an integrated platform where strategy providers and investors meet.
Nicholas Chrysochos, Executive Director of B2Prime, remarks:
"Numerous hedge funds, money managers, professional traders, algorithmic traders, systematic traders, and high-net-worth individuals have shown a keen interest in accessing our extensive liquidity pool. In response to this growing demand, we have chosen cTrader as the platform through which these clients can access our bespoke liquidity products across a wide range of jurisdictions. We are licensed by CySEC, allowing us to serve the entire EU market, and we also hold licenses in Mauritius and Seychelles. This strategic growth is part of our commitment to helping our clients excel in competitive global markets."
Currently, B2Prime has several outstanding platforms, namely OneZero, PrimeXM, now cTrader, and FIX API connectivity.
Ilia Iarovitcyn, CEO of Spotware Systems, comments:
“We are excited to continuously develop our liquidity provision network, expand the asset offering and enhance the reliability of our trading environment. Partnering with B2Prime contributes to delivering competitive pricing and an exceptional trading experience to our end users. With our cutting-edge technology and B2Prime’s strategic growth, we are confident in driving innovation and success for our clients globally.”
The collaboration between B2Prime and Spotware extends B2Prime’s range of services and significantly enhances cTrader’s liquidity offering, making it even more competitive. With a portfolio of over 200 instruments across six asset classes—FOREX, Crypto CFDs, Spot Indices, Precious Metals, Commodities, and NDFs—B2Prime offers one of the most comprehensive liquidity solutions on the market.
The company guarantees access to the deepest liquidity pools sourced from the most reputable providers, ensuring competitive spreads and swift execution. Additionally, B2Prime provides multi-currency prime margin accounts and an institutional tiered-margin approach.
Spotware is a global technology provider, successfully delivering cutting-edge fintech solutions and infrastructure for over 14 years. The company has cultivated a sophisticated network of 240+ brokers and prop firms. With a user base exceeding 4 million traders, cTrader, Spotware’s flagship platform, stands out for its unparalleled innovativeness and user-friendly UI, setting new standards across the industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610848632/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom